-
Review
Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion.
- W Toller, M Heringlake, F Guarracino, L Algotsson, J Alvarez, H Argyriadou, T Ben-Gal, V Černý, B Cholley, A Eremenko, J L Guerrero-Orriach, K Järvelä, N Karanovic, M Kivikko, P Lahtinen, V Lomivorotov, R H Mehta, Š Mušič, P Pollesello, S Rex, H Riha, A Rudiger, M Salmenperä, L Szudi, L Tritapepe, D Wyncoll, and A Öwall.
- Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Graz, Graz, Austria. Electronic address: wolfgang.toller@medunigraz.at.
- Int. J. Cardiol. 2015 Apr 1;184:323-36.
AbstractIn cardiac surgery, postoperative low cardiac output has been shown to correlate with increased rates of organ failure and mortality. Catecholamines have been the standard therapy for many years, although they carry substantial risk for adverse cardiac and systemic effects, and have been reported to be associated with increased mortality. On the other hand, the calcium sensitiser and potassium channel opener levosimendan has been shown to improve cardiac function with no imbalance in oxygen consumption, and to have protective effects in other organs. Numerous clinical trials have indicated favourable cardiac and non-cardiac effects of preoperative and perioperative administration of levosimendan. A panel of 27 experts from 18 countries has now reviewed the literature on the use of levosimendan in on-pump and off-pump coronary artery bypass grafting and in heart valve surgery. This panel discussed the published evidence in these various settings, and agreed to vote on a set of questions related to the cardioprotective effects of levosimendan when administered preoperatively, with the purpose of reaching a consensus on which patients could benefit from the preoperative use of levosimendan and in which kind of procedures, and at which doses and timing should levosimendan be administered. Here, we present a systematic review of the literature to report on the completed and ongoing studies on levosimendan, including the newly commenced LEVO-CTS phase III study (NCT02025621), and on the consensus reached on the recommendations proposed for the use of preoperative levosimendan.Copyright © 2015. Published by Elsevier Ireland Ltd.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*
,_underline_
or**bold**
. - Superscript can be denoted by
<sup>text</sup>
and subscript<sub>text</sub>
. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3.
, hyphens-
or asterisks*
. - Links can be included with:
[my link to pubmed](http://pubmed.com)
- Images can be included with:
![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
- For footnotes use
[^1](This is a footnote.)
inline. - Or use an inline reference
[^1]
to refer to a longer footnote elseweher in the document[^1]: This is a long footnote.
.